Biocon Share Price
Sector: Biotechnology & Drugs
341.50 +2.00 (0.59%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
338.75
Today’s High
345.00
52 Week Low
270.00
52 Week High
404.60
341.60 +2.20 (0.65%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
338.50
Today’s High
345.15
52 Week Low
269.55
52 Week High
404.70
Key Metrics
- Market Cap (In Cr) 41000.49
- Beta 0.89
- Div. Yield (%) 0.15
- P/B 1.88
- TTM P/E 40.34
- Peg Ratio 2.51
- Sector P/E 34.93
- D/E 0.01
- Open Price 339.5
- Prev Close 339.5
Biocon Analysis
Price Analysis
-
1 Week2.88%
-
3 Months-2.85%
-
6 Month1.07%
-
YTD-7.1%
-
1 Year11.01%
Risk Meter
- 39% Low risk
- 39% Moderate risk
- 39% Balanced Risk
- 39% High risk
- 39% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 5
- 5
- 5
- 5
- Buy
- 4
- 4
- 4
- 4
- Hold
- 3
- 3
- 3
- 3
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 15
- 15
- 15
- 15
Biocon Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 15261.7
- Selling/ General/ Admin Expenses Total
- 3144.4
- Depreciation/ Amortization
- 1687
- Other Operating Expenses Total
- 3753.5
- Total Operating Expense
- 13685.9
- Operating Income
- 1575.8
- Net Income Before Taxes
- 1886.6
- Net Income
- 1013.3
- Diluted Normalized EPS
- 7.85
- Period
- 2025
- Total Assets
- 58797.3
- Total Liabilities
- 37153.3
- Total Equity
- 21644
- Tangible Book Valueper Share Common Eq
- -45.09
- Period
- 2025
- Cashfrom Operating Activities
- 4061.2
- Cashfrom Investing Activities
- -234.1
- Cashfrom Financing Activities
- -1854
- Net Changein Cash
- 2004.3
- Period
- 2024
- Total Revenue
- 14755.7
- Selling/ General/ Admin Expenses Total
- 5341.8
- Depreciation/ Amortization
- 1568.8
- Other Operating Expenses Total
- -29.9
- Total Operating Expense
- 12878.6
- Operating Income
- 1877.1
- Net Income Before Taxes
- 1525.2
- Net Income
- 1022.5
- Diluted Normalized EPS
- 7.89
- Period
- 2024
- Total Assets
- 56070.7
- Total Liabilities
- 36287
- Total Equity
- 19783.7
- Tangible Book Valueper Share Common Eq
- -57.27
- Period
- 2024
- Cashfrom Operating Activities
- 2953.9
- Cashfrom Investing Activities
- -1004.5
- Cashfrom Financing Activities
- -2332.7
- Net Changein Cash
- -380.4
- Period
- 2023
- Total Revenue
- 11174.2
- Selling/ General/ Admin Expenses Total
- 3820.3
- Depreciation/ Amortization
- 1113.1
- Other Operating Expenses Total
- -348.9
- Total Operating Expense
- 9622.5
- Operating Income
- 1551.7
- Net Income Before Taxes
- 897.1
- Net Income
- 462.7
- Diluted Normalized EPS
- 4.35
- Period
- 2023
- Total Assets
- 52042.8
- Total Liabilities
- 34175.9
- Total Equity
- 17866.9
- Tangible Book Valueper Share Common Eq
- -73.26
- Period
- 2023
- Cashfrom Operating Activities
- 1852.5
- Cashfrom Investing Activities
- -14281.8
- Cashfrom Financing Activities
- 13048.7
- Net Changein Cash
- 641.1
- Period
- 2022
- Total Revenue
- 8184
- Selling/ General/ Admin Expenses Total
- 2920.9
- Depreciation/ Amortization
- 814.2
- Other Operating Expenses Total
- -445.1
- Total Operating Expense
- 7079.5
- Operating Income
- 1104.5
- Net Income Before Taxes
- 983.1
- Net Income
- 648.4
- Diluted Normalized EPS
- 5.97
- Period
- 2022
- Total Assets
- 20394
- Total Liabilities
- 11961.5
- Total Equity
- 8432.5
- Tangible Book Valueper Share Common Eq
- 59.28
- Period
- 2022
- Cashfrom Operating Activities
- 1210.4
- Cashfrom Investing Activities
- -1699.1
- Cashfrom Financing Activities
- 242.1
- Net Changein Cash
- -243.3
- Period
- 2021
- Total Revenue
- 7143.1
- Selling/ General/ Admin Expenses Total
- 2762.8
- Depreciation/ Amortization
- 715.1
- Other Operating Expenses Total
- -326.6
- Total Operating Expense
- 6025.8
- Operating Income
- 1117.3
- Net Income Before Taxes
- 1067.7
- Net Income
- 740.5
- Diluted Normalized EPS
- 5.1
- Period
- 2021
- Total Assets
- 18522.3
- Total Liabilities
- 10895.4
- Total Equity
- 7626.9
- Tangible Book Valueper Share Common Eq
- 53.56
- Period
- 2021
- Cashfrom Operating Activities
- 1125.9
- Cashfrom Investing Activities
- -3624.7
- Cashfrom Financing Activities
- 2564
- Net Changein Cash
- 72.3
- Period
- 2020
- Total Revenue
- 6300.5
- Selling/ General/ Admin Expenses Total
- 2352.4
- Depreciation/ Amortization
- 552.2
- Other Operating Expenses Total
- -326.4
- Total Operating Expense
- 5180.8
- Operating Income
- 1119.7
- Net Income Before Taxes
- 1214.9
- Net Income
- 748.2
- Diluted Normalized EPS
- 6.13
- Period
- 2020
- Total Assets
- 14443.8
- Total Liabilities
- 7738
- Total Equity
- 6705.8
- Tangible Book Valueper Share Common Eq
- 46.97
- Period
- 2020
- Cashfrom Operating Activities
- 1283.1
- Cashfrom Investing Activities
- -1558.9
- Cashfrom Financing Activities
- 387.6
- Net Changein Cash
- 165.4
- Period
- 2025-03-31
- Total Revenue
- 4417
- Selling/ General/ Admin Expenses Total
- 811.1
- Depreciation/ Amortization
- 436.3
- Other Operating Expenses Total
- 1054.8
- Total Operating Expense
- 3754.7
- Operating Income
- 662.3
- Net Income Before Taxes
- 486.8
- Net Income
- 344.5
- Diluted Normalized EPS
- 2.71
- Period
- 2025-03-31
- Total Assets
- 58797.3
- Total Liabilities
- 37153.3
- Total Equity
- 21644
- Tangible Book Valueper Share Common Eq
- -45.09
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 4061.2
- Cashfrom Investing Activities
- -234.1
- Cashfrom Financing Activities
- -1854
- Net Changein Cash
- 2004.3
- Period
- 2024-12-31
- Total Revenue
- 3821.4
- Selling/ General/ Admin Expenses Total
- 788.3
- Depreciation/ Amortization
- 425.4
- Other Operating Expenses Total
- 922
- Total Operating Expense
- 3476.9
- Operating Income
- 344.5
- Net Income Before Taxes
- 155.9
- Net Income
- 25.1
- Diluted Normalized EPS
- 0.13
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3590.4
- Selling/ General/ Admin Expenses Total
- 789.6
- Depreciation/ Amortization
- 419.9
- Other Operating Expenses Total
- 932.8
- Total Operating Expense
- 3298.9
- Operating Income
- 291.5
- Net Income Before Taxes
- 98.4
- Net Income
- -16
- Diluted Normalized EPS
- -0.27
- Period
- 2024-09-30
- Total Assets
- 57127.9
- Total Liabilities
- 36134.7
- Total Equity
- 20993.2
- Tangible Book Valueper Share Common Eq
- -47.47
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 705.4
- Cashfrom Investing Activities
- 966.2
- Cashfrom Financing Activities
- -1278.6
- Net Changein Cash
- 403.1
- Period
- 2024-06-30
- Total Revenue
- 3432.9
- Selling/ General/ Admin Expenses Total
- 755.4
- Depreciation/ Amortization
- 405.4
- Other Operating Expenses Total
- 874.4
- Total Operating Expense
- 3185.9
- Operating Income
- 247
- Net Income Before Taxes
- 1145.5
- Net Income
- 659.7
- Diluted Normalized EPS
- 5.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3917.1
- Selling/ General/ Admin Expenses Total
- 741.6
- Depreciation/ Amortization
- 407
- Other Operating Expenses Total
- 930.1
- Total Operating Expense
- 3417
- Operating Income
- 500.1
- Net Income Before Taxes
- 319
- Net Income
- 135.5
- Diluted Normalized EPS
- 1.18
- Period
- 2024-03-31
- Total Assets
- 56070.7
- Total Liabilities
- 36287
- Total Equity
- 19783.7
- Tangible Book Valueper Share Common Eq
- -57.27
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2953.9
- Cashfrom Investing Activities
- -1004.5
- Cashfrom Financing Activities
- -2332.7
- Net Changein Cash
- -380.4
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Biocon Technical
Moving Average
SMA
- 5 Day334.77
- 10 Day336.22
- 20 Day330.67
- 50 Day330.51
- 100 Day346.58
- 300 Day348.73
Biocon Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Glaxosmithkline Pharmaceutical
- 2805.75
- -21.85
- -0.77
- 3147.45
- 1924.3
- 47540.34
- Glenmark Pharmaceuticals
- 1438.5
- -8.8
- -0.61
- 1830.05
- 985.6
- 40687.35
- Biocon
- 341.5
- 2
- 0.59
- 404.6
- 270
- 41000.49
- Suven Pharmaceuticals
- 0
- 0
- 0
- 0
- 0
- 0
- Ipca Laboratories
- 1437.45
- 44.95
- 3.23
- 1757.65
- 1060.95
- 36448.87
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Glaxosmithkline Pharmaceutical
- 51.85
- 24.56
- 29.26
- 16.77
- Glenmark Pharmaceuticals
- -
- 5.21
- 1.61
- 1.43
- Biocon
- 43.24
- 1.88
- 5.73
- 8.83
- Suven Pharmaceuticals
- 88.97
- 13.14
- 27.91
- 33.21
- Ipca Laboratories
- 53.87
- 5.58
- 14.98
- 12.25
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 08-May-25
- Audited Results & Final Dividend
- 23-Apr-25
- Others
- 04-Apr-25
- To consider Fund Raising
- 30-Jan-25
- Quarterly Results & Others
- 27-Jan-25
- Others
- 30-Oct-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 16-May-24
- Audited Results & Final Dividend
- 08-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-25
- 08-May-25
- AGM
- 06-Jun-25
- 05-May-25
- POM
- 02-Apr-25
- 27-Feb-25
- POM
- 24-Sept-24
- 23-Aug-24
- POM
- 09-Aug-24
- 16-May-24
- AGM
- 30-Nov-23
- 27-Oct-23
- POM
- 11-Aug-23
- 23-May-23
- AGM
- 24-Jul-23
- 20-Jun-23
- POM
- 28-Jul-22
- 29-Apr-22
- AGM
- 23-Jul-21
- 28-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 08-May-25
- 04-Jul-25
- -
- 0.5
- 16-May-24
- 05-Jul-24
- 05-Jul-24
- 0.5
- 24-May-23
- 07-Jul-23
- 07-Jul-23
- 1.5
- 28-Apr-22
- 01-Jul-22
- 30-Jun-22
- 0.5


